26 completed, 6 unknown, 2 recruiting, 1 not yet recruiting. 37 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 26, Unknown 6, Recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow Coronary Heart Disease: new trials by email Literature Review of Coronary Heart Disease trials Research Report on Coronary Heart Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo - Coronary Disease, Coronary Heart Disease | Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 150 | 2027-09-01 | 2026-08-19 |
| A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease Yiyang Huoluo Decoction, conventional western medicine treatment - Coronary Heart Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Recruiting | Xia Liang | 30 | 2026-01-16 | 2026-03-25 |
| Study of Sivelestat Sodium in OPCABG Sivelestat Sodium injection 2 h after OPCABG for 72 h, Saline (0.9% NaCl) - Coronary Heart Disease, Coronary Artery Disease | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 62 | 2025-08-01 | 2025-08-12 |
| A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) MAS825, MAS825 Placebo, DFV890 - Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP) | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2024-02-15 | 2026-04-09 |
| A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP DFV890, DFV890 Placebo - Coronary Heart Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 24 | 2023-10-16 | 2026-04-09 |
| Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI) Selective PCI, Bivalirudin - Coronary Heart Disease | Phase 2 | Unknown | Qian Gong | 200 | 2018-09-15 | 2018-08-20 |
| Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease Doxycycline Capsule, Azithromycin Capsule, Rifabutin Oral Capsule - Coronary Heart Disease, Chlamydophila Pneumoniae Infections | Phase 2 | Terminated | Cadrock Pty. Ltd. | 20 | 2018-04-04 | 2021-08-02 |
| Effects of Yangxinshi Pills on the Exercise Tolerance of the Patients With Coronary Heart Disease Yangxinshi pill, conventional coronary heart disease medicine, Placebos - Coronary Heart Disease | Phase 2 | Unknown | Affiliated Hospital of Changchun University of Chinese Medicine | 90 | 2017-06-01 | 2018-03-27 |
| Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina Xuesaitong soft capsule, Placebo oral capsule - Coronary Heart Disease, Unstable Angina | Phase 2 | Unknown | Jie Wang | 70 | 2017-03-20 | 2017-03-17 |
| High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV Pravastatin, Rosuvastatin - HIV Infection, Coronary Heart Disease | Phase 2 | Completed | Matthew Feinstein | 10 | 2016-11-01 | 2022-10-18 |
| GLP-1 Loading During Elective Percutaneous Coronary Intervention GLP-1, placebo - Angina Pectoris, Myocardial Infarction | Phase 2 | Unknown | Papworth Hospital NHS Foundation Trust | 193 | 2015-03-01 | 2018-06-06 |
| Liraglutide to Improve corONary Haemodynamics During Exercise streSS Liraglutide, Placebo - Ischaemic Heart Disease, Coronary Heart Disease | Phase 2 | Completed | King's College London | 26 | 2014-01-01 | 2015-05-20 |
| Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery Glutamine, Ringer's solution - Rheumatic Heart Disease, Coronary Heart Disease | Phase 2 | Completed | Yuejiang Liu | 33 | 2013-01-01 | 2014-05-28 |
| A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease MPSK3169A, Placebo - Coronary Heart Disease | Phase 2 | Completed | Genentech, Inc. | 248 | 2012-05-01 | 2016-11-02 |
| The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease Xuesaitong soft capsule, Xuesaitong soft capsule Placebo - Coronary Heart Disease, Unstable Angina | Phase 2 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 70 | 2012-05-01 | 2014-01-14 |
| The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols Tetraspan, acetated Ringer's solution - Coronary Heart Disease | Phase 2 | Completed | Haukeland University Hospital | 40 | 2011-11-01 | 2015-05-12 |
| Optimizing Expectations in Cardiac Surgery Patients Expectation Manipulation Intervention, Supportive Therapy - Coronary Artery Bypass Graft Surgery (CABG), Patients' Expectations | Phase 2 | Completed | Philipps University Marburg | 124 | 2011-07-01 | 2016-02-03 |
| Treatment of Coronary Heart Disease With Amiloride Amiloride, Nitrates, clopidogrel, aspirin, statins - Coronary Heart Disease | Phase 2 / Phase 3 | Completed | University of Carabobo | 70 | 2009-02-01 | 2012-06-11 |
| Immunoadsorption and Immunoglobulin Substitution for Heart Failure After Myocardial Infarction Immunoadsorption / Immunoglobulin substitution - Heart Failure, Coronary Heart Disease | Phase 1 / Phase 2 | Withdrawn | University Medicine Greifswald | 2008-09-01 | 2016-05-11 | |
| A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease Dalcetrapib (RO4607381), Placebo - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 130 | 2008-03-01 | 2020-01-03 |
Showing 20 of 37. Sign in to see all of them.
Coronary Disease (37) · Atherosclerosis (4) · Coronary Artery Disease (4) · Myocardial Ischemia (3) · Angina, Unstable (2) · Heart Failure (2) · Hyperlipidemias (2) · Inflammation (2) · Stroke (2) · Angina Pectoris (1) · Angina, Stable (1) · Cardiovascular Diseases (1) · Cerebral Infarction (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1)
Heart Diseases (37) · Vascular Diseases (37) · Cardiovascular Diseases (36) · Myocardial Ischemia (34) · Pathological Conditions, Signs and Symptoms (8) · Arterial Occlusive Diseases (7) · Arteriosclerosis (7) · Signs and Symptoms (5) · Chest Pain (4) · Neurologic Manifestations (4) · Pain (4) · Pathologic Processes (4) · Angina Pectoris (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3)
dalcetrapib (4) · Meditation (2) · (1-6)-alpha-glucomannan (1) · Amiloride (1) · Aspirin (1) · Azithromycin (1) · Clopidogrel (1) · Coronary Artery Bypass (1) · Dietary Fiber (1) · Doxycycline (1) · Glucagon-Like Peptide 1 (1) · Glutamine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Liraglutide (1) · Milk (1)
Hoffmann-La Roche (4) · Novartis Pharmaceuticals (2) · Affiliated Hospital of Changchun University of Chinese Medicine (1) · Affiliated Hospital of Nantong University (1) · Cadrock Pty. Ltd. (1) · Copenhagen University Hospital, Rigshospitalet (1) · Daiichi Sankyo (1) · Genentech, Inc. (1) · GlaxoSmithKline (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Haukeland University Hospital (1) · Imperial College London (1) · Jie Wang (1) · King's College London (1) · Lund University Hospital (1)
United States (12) · Germany (7) · China (6) · Canada (5) · United Kingdom (5) · Denmark (3) · Netherlands (2) · Norway (2) · South Africa (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Finland (1) · France (1)
Antonio J Delgado-Leon, MD (1) · Antonio R Delgado-Almeida, MD, FAHA, FACC, APS (1) · Astrid Hummel, MD (1) · C. Noel Bairey Merz, M.D. (1) · Carlos L Delgado-Leon, MD (1) · Daniel Beug, MD (1) · Donald Lloyd-Jones, MD (1) · Emerson Perin, MD, PhD (1) · Jens Kastrup, MD DMSc (1) · Jie Wang (1) · John French (1) · Lars R Herda, MD (1)
PMID 12595539, PMID 16554527, PMID 17583796, PMID 18308009, PMID 19843338, PMID 20464430, PMID 20689074, PMID 21118562, PMID 21128879, PMID 21908036, PMID 22345126, PMID 23149426, PMID 23942908, PMID 24135322, PMID 24211066, PMID 24241342, PMID 27536731, PMID 28069021, PMID 28343601, PMID 28606503, PMID 28846584, PMID 29199540, PMID 31277053, PMID 31813921, PMID 33002633, PMID 33579317, PMID 35266173, PMID 35522399, PMID 35784716, PMID 36389323, PMID 38769746, PMID 38811097, PMID 38886709, PMID 40148035, PMID 40932796
2023 (1), R01AT000226 (1)